Schäfer Eik, Scheer Christian, Saljé Karen, Fritz Anja, Kohlmann Thomas, Hübner Nils-Olaf, Napp Matthias, Fiedler-Lacombe Lizon, Stahl Dana, Rauch Bernhard, Nauck Matthias, Völker Uwe, Felix Stephan, Lucchese Guglielmo, Flöel Agnes, Engeli Stefan, Hoffmann Wolfgang, Hahnenkamp Klaus, Tzvetkov Mladen V
Department of Clinical Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany.
Department of Anesthesiology, University Medicine Greifswald, Greifswald, Germany.
Sci Rep. 2022 May 4;12(1):7249. doi: 10.1038/s41598-022-11103-0.
We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5-18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.
我们分析了德国东北部710例经PCR确诊的SARS-CoV-2感染门诊患者的症状和合并症,以此作为住院治疗的预测指标。在感染的前3天,常见症状为疲劳(71.8%)、关节痛/肌痛(56.8%)、头痛(55.1%)和干咳(51.8%)。嗅觉丧失(嗅觉减退)、味觉丧失(味觉减退)、呼吸困难和咳痰在感染4天后出现。第1天只有18%的参与者报告有嗅觉减退或味觉减退,但在第7至9天这一比例高达49%。并非所有报告味觉减退的参与者都报告有嗅觉减退。仅有味觉减退而无嗅觉减退的个体住院风险最高(比值比6.8,95%置信区间2.5 - 18.1)。他们还更常出现呼吸困难和恶心(比值比分别为3.0和2.9),这表明这些症状之间存在病理生理联系。与住院风险增加显著相关的其他症状还有呼吸困难、呕吐和发热。在基本参数和合并症方面,年龄>60岁、慢性阻塞性肺疾病(COPD)、既往中风、糖尿病、肾脏和心脏疾病也与住院风险增加有关。总之,由于发病较晚,味觉减退和嗅觉减退在SARS-CoV-2的鉴别诊断中可能作用有限。然而,区分味觉减退和嗅觉减退可能有助于评估住院风险。